COMPARATIVE ANALYSIS OF THE COURSE OF CHRONIC KIDNEY DISEASE (CKD) IN PATIENTS WITH DIFFERENT STAGES OF RENAL CANCER AFTER RADICAL AND CYTOREDUCTIVE NEPHRECTOMY
DOI:
https://doi.org/10.11603/2415-8798.2017.3.8088Keywords:
kidney cancer, chronic kidney disease, radical nephrectomy, cytoreductive nephrectomy.Abstract
Renal cell carcinoma (RCC) ranks tenth in terms of the incidence rate among all malignant diseases and amounts to 2 %. In 30 % of newly diagnosed cases of RCC, the presence of distant metastases is diagnosed, and the life expectancy of this group of patients does not exceed 12 months from the time of detection of the disease.
The aim of the study – to conduct a comparative analysis of the course of chronic kidney disease in patients at different stages of renal cell carcinoma after radical and cytodectile nephrectomy.
Materials and Methods. The study was attended by 53 patients with renal cell carcinoma (RCC) complicated by chronic kidney disease. All patients had a radical or cytoreductile nephrectomy for RCC, and a retrospective analysis of the treatment outcomes was performed thereafter. All patients undergo inpatient treatment in the Urological Department of the Lviv Regional Clinical Hospital and in the Urological Department of the Lviv Oncology Regional Treatment and Diagnostic Center.
Results and Discussion. Analyzing the data presented in Table 1, it can be noted that prior to the surgical treatment of kidney cancer, in 2 stages of the CKD, 9 (42. 9 %) patients in the first group and 23 (71. 9 %) patients in the second group. Accordingly, the 3rd stage of CKD was diagnosed in 7 (33.3 %) patients in the first group and in 7 (21. 9 %) patients in the second group. 3rd stage of CKD was observed in 4 (19.0 %) patients in the first group and in 2 (6.3 %) patients in the second group. At the fourth stage of the CKD, only 1 (4.8 %) patients in the first group underwent surgical treatment. The fifth stage of the CKD was not observed in any case. Analyzing the data presented in Table 2, it can be noted that three months after the surgical treatment of kidney cancer, progression of CKD was observed in 11 (52.4 %) patients in the first group and 9 (28.1 %) patients in the second group.
Conclusions. Carrying out cytoreductive nephrectomy in patients with RCC increases the risk of CKD progression by 24.3 % comparing with the implementation of radical nephrectomy.
References
Kondratenko, A.V., Mravchkovsky, V.V., Yakovlev, P.G., Sakalo, A.V., Grigorenko, V.N., Sakalo, V.S. … Kuranov, Yu.Yu. (2009). Tsitoreduktivnaya nefrektomiya v lechenii bolnykh s metastaticheskim svetlokletochnym rakom pochki [Tsitoreductive nephrectomy in the treatment of patients with metastatic, light cell-derived kidney cancer]. Onkologiya – Oncology, (11), 3, 228–230 [in Russian].
Sigitova, O.N. & Arkhipov, E.V. (2014). Khronicheskaya bolezn pochek: novoye v klassifikatsii, diagnostike, nefroprotektsii. Vestnik sovremennoy klinicheskoy meditsiny Chronic kidney disease: new in classification, diagnostics, nephroprotection. Bulletin of Modern Clinical Medicine, 2014, Volume 7, Appendix 1 p. 103–106 [in Russian].
Stakhovsky, E.A., Voilenko, O.A., Vukalovich, P.S., Vitruk, Yu.V., Stakhovsky, A.E., Kotov, V.A. (2012). Tsitoreduktivnaya rezektsiya pochki v lechenii metastaticheskogo pochechno – kletochnogo raka [Cytoreductive renal resection in the treatment of metastatic renal cell carcinoma]. Klinicheskaya onkologiya – Clinical Oncology, 7 (3), 1-4 [in Russian].
Strokov, A.G., Gurevich, K.Ya., Ilyin, A.P., Denisov, A.Yu., Zemchenkov A.Yu., Andrusev, A.M., … Shutov, E.V. (2017). Lecheniye patsiyentov s khronicheskoy bolezn'yu pochek 5 stadiy (KHBP 5) metodami gemodializa i gemodiafiltratsii. Klinicheskiye rekomendatsii [Treatment of patients with chronic kidney disease 5 stages (CKD 5) by hemodialysis and hemodiafiltration methods. Clinical recommendations]. Nefrologiya – Nephrology, 21(3), 92–111 [in Russian]. DOI: 10.24884/1561-6274-2017-3-92-111
Shipov, E.M. & I.N. Bobkova (2016). Shipova, E.M. (Eds.) Khronicheskaya bolezn pochek i nefroprotektivnaya terapiya: metod. Rukovodstvo dlya vrachey [Chronic kidney disease and nephroprotective therapy: method. Manual for doctors]. Moskva, 76 [in Russian].
Bex, A., Ljungberg, B., Hein van Poppel & Powles, T. (2016). The Role of Cytoreductive Nephrectomy: European Association of Urology Recommendations in 2016 December, (70), Issue 6, 901–905 [in Russian].
Bex, A. & Powles, T. (2012). Selecting patients for cytoreductive nephrectomy in advanced renal cell carcinoma: who and when. Expert Rev Anticancer Ther. 2, 12, 787–797.
Biswas, B., Dabkara, D., Ganguly, S., Eswaran, P. & Ghosh, J. (2017). Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy: Scientifically Relevant or Natural Selection? Journal of clinical oncology, (35), 11, april 10, 1265–1266.
Chery, L.J., Karam, J.A. & Wood C.G. (2016). Cytoreductive nephrectomy for metastatic renal cell carcinoma Clin Adv Hematol Oncol., 14(9), 696–703.
Flanigan, R.C., Mickisch, G. & Sylvester, R. (2004). Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J. Urol., 171(3), 1071–1076.
Fogarty, D.G., Tall, M.W. & Marsden, P.A. (2012). (Eds). Brenner and Rector's the Kidney. A stepped care approach to the management of chronic kidney disease. In: 9th ed. Philadelphia, PA: Elsevier Saunders, chap 61.
Hanna, N., Sun, M. & Meyer, C.P. (2016). Survival analyses of patients with metastatic renal cancer treated with targeted therapy with or without cytoreductive nephrectomy: A National Cancer Data Base Study. J. Clin. Oncol., 34, 3267–3275.
Ljungberg, B., Cowan, N.C. & Hanbury, D.C. (2010). European Association of Urology Guideline Group. EAU guidelines on renal cell carcinoma: the 2010 update. Eur. Urol., 58(3), 398–406.
Petrelli, F., Coinu, A. & Vavassori, I. (2016). Cytoreductive nephrectomy in metastatic renal cell carcinoma treated with targeted therapies: A systematic review with a meta-analysis. Clin Genitourin Cancer, 14, 465–472.
Song, C., Bang, J.K., Park, H.K. & Ahn, H. (2009). Factors influencing renal function reduction after partial nephrectomy. J. Urol., 181(1), 48–53.
Stephen, H. (2015). Cytoreductive nephrectomy and its role in the present-day period of targeted therapy Ther Adv Urol. Oct., 7(5), 275–285.
Thompson. R.H., Hill. J.R. & Babayev, Y. (2009). Metastatic renal cell carcinoma risk according to tumor size. J. Urol., 182(1), 41–5.
Tsao, C., Small, A., Kates, M., Moshier, E., Wisnivesky, J. & Gartrell B. (2013). Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis. World J Urol., 31, 1535–1539.
Xiao, W.J., Zhu, Y. & Dai, B. (2015). Assessment of survival of patients with metastatic clear cell renal cell carcinoma after radical cytoreductive nephrectomy versus no surgery: A SEER analysis. Int Braz J Urol., 41, 288–295.
Downloads
Published
How to Cite
Issue
Section
License
Authors who sent their manuscript to "Вісник наукових досліджень. Bulletin of Scientific Research" Surgery agree to the following terms:
a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal. 
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
